Recombinant fowlpox virus vaccines against Australian virulent Marek's disease virus: gene sequence analysis and comparison of vaccine efficacy in specific pathogen free and production chickens.
We have cloned and sequenced the glycoprotein genes gB, gC and gD of the Australian virulent Marek's disease virus (MDV) isolate Woodlands No. 1. The glycoprotein gB and gC sequences were identical to the homologs of other virulent MDV type 1 strains, and the glycoprotein gD sequence contained only one unique amino acid substitution. Recombinant fowlpox viruses (rFPVs) expressing the MDV glycoprotein genes were constructed and their efficacy as vaccines was evaluated in specific pathogen free (SPF) and production chickens. Vaccination with the FPV-gB recombinant protected SPF chickens from Marek's disease mortality and tumour formation following challenge with virulent MDV Woodlands No. 1. The degree of protection from Marek's disease was dependent on the vaccine dose and route of inoculation. The rFPVs expressing gC or gD did not provide protection from Marek's disease. A rFPV expressing both gB and gC did not provide enhanced protection in comparison with the rFPV-gB alone. The rFPV-gB vaccine failed to protect commercial chickens from MD mortality and provided little protection from tumour formation in comparison with the commercial herpesvirus of turkey (HVT) vaccine. The failure to provide protection against MD may be related to the impact of maternally derived immunity to MDV and FPV and possibly the genotype of the chickens.
Heine
H G
HG
CSIRO, Australian Animal Health Laboratory, Geelong, Victoria. hans.heine@aahl.dah.csiro.au
Foord
A J
AJ
Young
P L
PL
Hooper
P T
PT
Lehrbach
P R
PR
Boyle
D B
DB
D000595:Amino Acid Sequence; D000818:Animals; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology; D002645:Chickens; D003001:Cloning, Molecular; D005587:Fowlpox virus / Q000235:genetics* / Q000276:immunology*; D008381:Herpesvirus 2, Gallid / Q000235:genetics* / Q000276:immunology* / Q000472:pathogenicity; D008380:Marek Disease / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D008969:Molecular Sequence Data; D017422:Sequence Analysis, DNA; D013047:Specific Pathogen-Free Organisms; D014614:Vaccines, Synthetic / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D014774:Virulence
D000956:Antigens, Viral; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C072811:glycoprotein B, Marek's disease virus; C086097:glycoprotein C, Marek's disease virus; C102727:glycoprotein D, Marek's disease virus